Similarly, Patel et al. [31] observed that JAK/STAT inhibition with ruxolitinib re-sensitized resistant NSCLC cells to VSV-IFNβ-mediated oncolysis. This evidence concerns the gene IFNB1 and non-small cell lung carcinoma.